scholarly journals The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease

2003 ◽  
Vol 1 (5) ◽  
pp. 982-986 ◽  
Author(s):  
M. R. Nijziel ◽  
R. Van Oerle ◽  
D. Hellenbrand ◽  
E. C. M. Van Pampus ◽  
H. F. P. Hillen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Metastatic Disease ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Plasminogen Activator Receptor

Urokinase-type plasminogen activator in plasma from breast cancer patients

1988 ◽  
Vol 24 (9) ◽  
pp. 1553
Author(s):  
F. Bach ◽  
J. Grøndahl-Hansen ◽  
N. Agerlin ◽  
P. Munkholm-Larsen ◽  
L.S. Nielsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator

Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers

2002 ◽  
Vol 30 (2) ◽  
pp. 207-210 ◽  
Author(s):  
M. J. Duffy
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Prospective Trial ◽  
Axillary Node ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Pai 1

Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis. Multiple studies have shown that breast cancer patients whose primary cancer contains high levels of uPA have a significantly worse outcome than patients with low levels. As a prognostic marker for breast cancer the information supplied by uPA is both independent of traditionally used factors and significant in the important subgroup of axillary-node patients. Paradoxically, high levels of plasminogen activator inhibitor-1 (PAI-1), an endogenous inhibitor of uPA, also predict for aggressive disease. Recently, the prognostic impact of both uPA and PAI-1 in axillary node-negative breast cancer was confirmed using two different Level 1 Evidence studies, i.e. in both a randomized prospective trial and a pooled analysis. Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients

Sign in / Sign up

Export Citation Format

Share Document